DRAFT/ADVISORY/CONSULTATIVE/DELIBERATIVE/CONFIDENTIAL

References

1 Porter J, Jick H. 1980, Jan 10. Addiction rare in patients treated with narcotics. N Engl J Med. 302(2):123.

2 Leung PTM, Macdonald EM, Stanbrook MB, Dhalla IA, Juurlink DN. 2017, Jun 1. A 1980 Letter on the Risk of Opioid Addiction. N Engl J Med. 376(22):2194-2195.

3 Chronic use of opioid analgesics in non-malignant pain: report of 38 cases. Portenoy RK, Foley KM. Pain. 1986 May;25(2):171-86. PMID: 2873550 https://www.ncbi.nlm.nih.gov/pubmed/2873550

4 Melzack R. 1990. The tragedy of needless pain. Sci Am. 262(2):27-33.

5 Portenoy RK. 1990, Feb. Chronic opioid therapy in nonmalignant pain. J Pain Symptom Manage (1 Suppl):S46-62.

6 Max MB. Improving outcomes of analgesic treatment: is education enough? Ann Intern Med. 1990;113(11):885889.

7 Max MB. Improving outcomes of analgesic treatment: is education enough? Ann Intern Med. 1990;113(11):885889.

8 PRESCRIPTION DRUGS OxyContin Abuse and Diversion and Efforts to Address the Problem. Available at https://www.gpo.gov/fdsys/pkg/GAOREPORTS-GAO-04-110/pdf/GAOREPORTS-GAO-04-110.pdf

9 Bloomquist ER. 1963 Aug. The addiction potential of oxycodone (Percodan). Calif Med. 99:127-30.

10 Van Zee A. 2009. The promoion and marketing of OxyContin: commercial triumph, public health tragedy. Am. J. Public Health 99:221­27.

11 Skolnick P. The Opioid Epidemic: Crisis and Solutions. Annu Rev Pharmacol Toxicol. 2017 Oct 2. [Epub ahead of print]

12 Dart RC, Surratt HL, Cicero TJ, Parrino MW, Severtson SG, et al. 2015. Trends in opioid analgesic abuse and mortality in the United States. N. Engl. J. Med. 372:241­48

13Cicero TJ, Ellis MS, Surratt HL, Kurtz SP. 2014. The changing face of heroin use in the United States: a retrospective analysis of the past 50 years. JAMA Psychiatry 71:821­26.

14 The United States Senate Committee on Finance Website. http://www.finance.senate.gov/chairmans-news/baucusgrassley-seek-diagnosiss-about-opioid-manufacturers-ties-to-medical-groups.

15 Lin DH, Lucas E, Murimi IB, Kolodny A, Alexander GC. 2017 Mar 1. Financial Conflicts of Interest and the Centers for Disease Control and Prevention's 2016 Guideline for Prescribing Opioids for Chronic Pain. JAMA Intern Med. 177(3):427-428.

16 Cicero TJ, Kurtz SP, Surratt HL, Ibanez GE, Ellis MS, Levi-Minzi MA, Inciardi JA. 2011 spring. Multiple Determinants of Specific Modes of Prescription Opioid Diversion. J Drug Issues. 41(2):283-304.

17 Campbell JN. APS 1995 Presidential address. Pain Forum. 1996;5:85­8.

18 Veterans Health Administration. Pain as the 5th Vital Sign Toolkit. https://www.va.gov/PAINMANAGEMENT/docs/Pain_As_the_5th_Vital_Sign_Toolkit.pdf.

2000.

19 Phillips DM. 2000, Jul 26. JCAHO pain management standards are unveiled. Joint Commission on Accreditation of Healthcare Organizations. JAMA. 284(4):428-9.

20 Baker DW. 2017, Mar 21. History of The Joint Commission's Pain Standards: Lessons for Today's Prescription Opioid Epidemic. JAMA. 317(11):1117-1118.

21 Baker DW. 2017, Mar 21. History of The Joint Commission's Pain Standards: Lessons for Today's Prescription Opioid Epidemic. JAMA. 317(11):1117-1118.

22 Chhabra N, Leikin JB. 2017, Jul 4. The Joint Commission and the Opioid Epidemic. JAMA. 318(1):91-92.

23 Baker DW. 2017, Jul 4. The Joint Commission and the Opioid Epidemic-Reply. JAMA. 318(1):92.

24 https://www.fsmb.org/Media/Default/PDF/FSMB/Advocacy/1998_grpol_Pain_Management_Guidelines.pdf

25 The Joint Commission. Pain management. https://www.jointcommission.org/topics/pain_management.aspx.

DRAFT/ADVISORY/CONSULTATIVE/DELIBERATIVE/CONFIDENTIAL

26 Van Zee A. 2009. The promotion and marketing of OxyContin: commercial triumph, public health tragedy. Am J Public Health. 99(2):221-227.

27 Pain Management and the Opioid Epidemic: Balancing Societal and Individual Benefi ts and Risks of Prescription Opioid Use, The National Academies Press. http://nationalacademies.org/hmd/Reports/2017/pain-managementand-the-opioid-epidemic.aspx.

28 Statement from FDA Commissioner Scott Gottlieb, M.D., on National Academies of Sciences, Engineering, and Medicine report on pain management and prescription opioid abuse. 2017, July 13. https://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm566958.htm.

29 https://www.cdc.gov/drugoverdose/data/prescribing.html

30 Daubresse M, Chang H, Yu Y, Viswanathan S, et al. Ambulatory diagnosis and treatment of nonmalignant pain in

the United States, 2000 ­ 2010.

Medical Care 2013; 51(10): 870-

878. http://dx.doi.org/10.1097/MLR.0b013e3182a95d86

31 Madras BK. 2017, May 1. The Surge of Opioid Use, Addiction, and Overdoses: Responsibility and Response of the US Health Care System. JAMA Psychiatry. 74(5):441-442.

32 Chiu AS, Healy JM, DeWane MP, Longo WE, Yoo PS. 2017, Jul 10. Trainees as Agents of Change in the Opioid
Epidemic: Optimizing the Opioid Prescription Practices of Surgical Residents. J Surg Educ. pii: S19317204(17)30157-5.

33 Madras BK. 2010 Feb. Office of National Drug Control Policy: a scientist in drug policy in Washington, DC. Ann N Y Acad Sci. 1187:370-402.

34 Madras BK, Compton WM, Avula D, Stegbauer T, Stein JB, Clark HW. 2009, Jan 1. Screening, brief interventions, referral to treatment (SBIRT) for illicit drug and alcohol use at multiple healthcare sites: comparison at intake and 6 months later. Drug Alcohol Depend. 99(1-3):280-95.

35 Gupta A, Lee LK, Mojica JJ, Nairizi A, George SJ. 2014, Sep-Oct. Patient perception of pain care in the United States: a 5-year comparative analysis of hospital consumer assessment of health care providers and systems. Pain Physician. 17(5):369-77.

36 Kelly S, Johnson GT, Harbison RD. 2016, Apr-Jun. "Pressured to prescribe" The impact of economic and
regulatory factors on South-Eastern ED physicians when managing the drug seeking patient. J Emerg Trauma Shock. 9(2):58-63.

37 O'Donnell JK, Halpin J, Mattson CL, Goldberger BA, Gladden RM. Deaths Involving Fentanyl, Fentanyl Analogs, and U-47700 -- 10 States, July­December 2016. MMWR Morb Mortal Wkly Rep. ePub: 27 October 2017. DOI: http://dx.doi.org/10.15585/mmwr.mm6643e1.

38 https://www.dea.gov/divisions/hq/2016/hq100416.shtml

39 Substance Abuse and Mental Health Services Administration. 2017. Results from the 2016 National Survey on

Drug Use and Health: Detailed Tables.

Table 1.28A and 1.28B. Retrieved from

https://www.samhsa.gov/data/sites/default/files/NSDUH-DetTabs-2016/NSDUH-DetTabs-2016.pdf, accessed on

October 26, 2017.

40 Han B, Compton WM, Blanco C, Crane E, Lee J, Jones CM. 2017. Prescription Opioid Use, Misuse, and Use Disorders in U.S. Adults: 2015 National Survey on Drug Use and Health. Ann Intern Med 167(5):293-301.

41 Han B, Compton WM, Blanco C, Crane E, Lee J, Jones CM. 2017. Prescription Opioid Use, Misuse, and Use Disorders in U.S. Adults: 2015 National Survey on Drug Use and Health. Ann Intern Med 167(5):293-301.

42 Center for Behavioral Health Statistics and Quality. (2016). Key substance use and mental health indicators in the United States: Results from the 2015 National Survey on Drug Use and Health (HHS Publication No. SMA 16 4984, NSDUH Series H-51). Retrieved from http://www.samhsa.gov/data/.

43 Substance Abuse and Mental Health Services Administration. 2017. Results from the 2016 National Survey on Drug Use and Health: Detailed Tables. Section 1 Tables and Table 5.17A. Retrieved from https://www.samhsa.gov/data/sites/default/files/NSDUH-DetTabs-2016/NSDUH-DetTabs-2016.pdf, accessed on October 26, 2017.

DRAFT/ADVISORY/CONSULTATIVE/DELIBERATIVE/CONFIDENTIAL

44 Substance Abuse and Mental Health Services Administration. 2017. Results from the 2016 National Survey on

Drug Use and Health: Detailed Tables.

Section 5 Tables. Retrieved from

https://www.samhsa.gov/data/sites/default/files/NSDUH-DetTabs-2016/NSDUH-DetTabs-2016.pdf, accessed on

October 26, 2017.

45 McCabe SE, West BT, Morales M, Cranford JA, Boyd CJ. 2007. Does early onset of non -medical use of prescription drugs predict subsequent prescription drug abuse and dependence? Results from a national study. Addiction. 102(12):1920­30.

46 Sullivan MD, Edlund MJ, Zhang L, Unutzer J, Wells KB. 2006. Association between mental health disorders, problem drug use, and regular prescription opioid use. Arch Intern Med. 166(19):2087­93.

47 Barry DT, Goulet JL, Kerns RK, Becker WC, Gordon AJ, Justice AC, Fiellin DA. 2011, May. Nonmedical use of prescription opioids and pain in veterans with and without HIV. Pain. 152(5):1133-8.

48 Galanter M, Dermatis H, Sampson C. 2014. Narcotics anonymous: a comparison of military veterans and nonveterans. J Addict Dis. 33(3):187-95.

49 Kaltenbach K, Berghella V, Finnegan L. 1998. Opioid dependence during pregnancy. Effects and management. Obstet Gynecol Clin North Am 25(1):139­51.

50 Becker WC, Sullivan LE, Tetrault JM, Desai RA, Fiellin DA. 2008. Non-medical use, abuse and dependence on
prescription opioids among U.S. adults: psychiatric, medical and substance use correlates. Drug Alcohol Depend 94(1­3):38­47.

51 Substance Abuse and Mental Health Services Administration. 2017. Results from the 2016 National Survey on

Drug Use and Health: Detailed Tables.

Table 1.28A and 1.28B. Retrieved from

https://www.samhsa.gov/data/sites/default/files/NSDUH-DetTabs-2016/NSDUH-DetTabs-2016.pdf, accessed on

October 26, 2017.

52 Wu LT, Zhu H, Swartz MS. 2016, Dec 1. Treatment utilization among persons with opioid use disorder in the United States. Drug Alcohol Depend. 169:117-127.

53 Katzman JG, Fore C, Bhatt S, Greenberg N, Griffin Salvador J, Comerci GC, Camarata C, Marr L, Monette R, Arora S, Bradford A, Taylor D, Dillow J, Karol S. 2016, Aug. Evaluation of American Indian Health Service Training in Pain Management and Opioid Substance Use Disorder. Am J Public Health. 106(8):1427-9.

54 O'Donnell JK, Halpin J, Mattson CL, Goldberger BA, Gladden RM. Deaths Involving Fentanyl, Fentanyl Analogs, and U-47700 -- 10 States, July­December 2016. MMWR Morb Mortal Wkly Rep. ePub: 27 October 2017. DOI: http://dx.doi.org/10.15585/mmwr.mm6643e1

55 Logan BK, Mohr ALA, Friscia M, Krotulski AJ, Papsun DM, Kacinko SL, Ropero-Miller JD, Huestis MA. 2017.
Reports of adverse events associated with use of novel psychoactive substances, 2013 -2016: A review. J Anal Toxicol 41(7):573-610.

56 Cicero TJ, Ellis MS, Kasper ZA. Increases in self-reported fentanyl use among a population entering drug treatment: The need for systematic surveillance of illicitly manufactured opioids. Drug Alcohol Depend. 2017 Aug 1;177:101-103.

57 O'Donnell JK, Halpin J, Mattson CL, Goldberger BA, Gladden RM. Deaths Involving Fentanyl, Fentanyl Analogs, and U-47700 -- 10 States, July­December 2016. MMWR Morb Mortal Wkly Rep. ePub: 27 October 2017. DOI: http://dx.doi.org/10.15585/mmwr.mm6643e1

58 Klar SA, Brodkin E, Gibson E, Padhi S, Predy C, Green C, Lee V. Notes from the Field: Furanyl-Fentanyl Overdose Events Caused by Smoking Contaminated Crack Cocaine - British Columbia, Canada, July 15-18, 2016. MMWR Morb Mortal Wkly Rep. 2016 Sep 23;65(37):1015-1016.

59 Fabregat-Safont D, Carbón X, Ventura M, Fornís I, Guillamón E, Sancho JV, Hernández F, Ibáñez M. 2017. Updating the list of known opioids through identification and characterization of the new opioid derivative 3,4 dichloro-N-(2-(diethylamino)cyclohexyl)-N-methylbenzamide (U-49900). Sci Rep 7(1):6338.

60 Zawilska JB. An Expanding World of Novel Psychoactive Substances: Opioids. Front Psychiatry. 2017 Jun 30;8:110. doi: 10.3389/fpsyt.2017.00110.

DRAFT/ADVISORY/CONSULTATIVE/DELIBERATIVE/CONFIDENTIAL
61 Fleming SW, Cooley JC, Johnson L, Frazee CC, Domanski K, Kleinschmidt K, Garg U. A nalysis of U-47700, a Novel Synthetic Opioid, in Human Urine by LC-MS-MS and LC-QToF. J Anal Toxicol. 2017 Apr 1;41(3):1730.
62 Prekupec MP, Mansky PA, Baumann MH. Misuse of Novel Synthetic Opioids: A Deadly New Trend. J Addict Med. 2017 Jul/Aug;11(4):256-265.
63 Ventura L, Carvalho F, Dinis-Oliveira RJ. 2017. Opioids in the frame of new psychoactive substances network: A complex pharmacological and toxicological issue. Curr Mol Pharmacol [Epub ahead of print].
64 Soares JX, Alves EA, Silva AMN, de Figueiredo NG, Neves JF, Cravo SM, Rangel M, Netto ADP, Carvalho F, Dinis-Oliveira RJ, Afonso CM. 2017. Street-like synthesis of Krokodil Results in the formation of an enlarged cluster of known and new morphinans. Chem Res Toxicol 30(8):1609-1621.
65 Substance Abuse and Mental Health Services Administration. 2017. Results from the 2016 National Survey on Drug Use and Health: Detailed Tables. Table 1.28A. Retrieved from https://www.samhsa.gov/data/sites/default/files/NSDUH-DetTabs-2016/NSDUH-DetTabs-2016.pdf on October 25, 2017.
66 Cicero TJ, Ellis MS, Kasper ZA. Psychoactive substance use prior to the development of iatrogenic opioid abuse: A descriptive analysis of treatment-seeking opioid abusers. Addict Behav. 2017 Feb;65:242-244.
67 Jarlenski M, Barry CL, Gollust S, Graves AJ, Kennedy-Hendricks A, Kozhimannil K. Polysubstance Use Among US Women of Reproductive Age Who Use Opioids for Nonmedical Reasons. Am J Public Health. 2017 Aug;107(8):1308-1310.
68 McCabe SE, West BT, Jutkiewicz EM, Boyd CJ. Multiple DSM-5 substance use disorders: A national study of US adults. Hum Psychopharmacol. 2017 Sep;32(5). [e-pub July 2017]
69 Han B, Compton WM, Jones CM, Cai R. 2015. Nonmedical prescription opioid use and use disorders among adults aged 18 through 64 years in the United States, 2003-2013. JAMA 314(14):1468-78.
70 Carlson RG, Nahhas RW, Martins SS, Daniulaityte R. 2016. Predictors of transition to heroin use a mong initially non-opioid dependent illicit pharmaceutical opioid users: A natural history study. Drug Alcohol Depend 160:12734.
71 Comer SD, Sullivan MA, Whittington RA, Vosburg SK, Kowalczyk WJ. 2008. Abuse liability of prescription opioids compared to heroin in morphine-maintained heroin abusers. Neuropsychopharmacology 33(5):1179-91.
72 Shah A, Hayes CJ, Martin BC. 2017. Factors influencing long-term opioid use among opioid naive patients: An examination of initial prescription characteristics and pain etiologies. J Pain [Epub ahead of print].
73 Stumbo SP, Yarborough BJ, McCarty D, Weisner C, Green CA. 2017. Patient-reported pathways to opioid use disorders and pain-related barriers to treatment engagement. J Subst Abuse Treat 73:47-54.
74 Manchikanti L, Helm S II, Fellows B, et al. 2012. Opioid epidemic in the United States. Pain Physician 15:Suppl:ES9-38.
75 Arria AM, Compton WM. 2017. Complexities in understanding and addressing the serious public health issues related to the nonmedical use of prescription drugs. Addict Behav 65:215-217.
76 Carlson RG, Nahhas RW, Martins SS, Daniulaityte R. 2016. Predictors of transition to heroin use among initially non-opioid dependent illicit pharmaceutical opioid users: A natural history study. Drug Alcohol Depend 160:12734.
77 Compton WM, Jones CM, Baldwin GT. 2016. Relationship between nonmedical prescription -opioid use and heroin use. N Engl J Med 374(2):154-63.
78 Compton WM, Jones CM, Baldwin GT. 2016. Nonmedical prescription-opioid use and heroin use. N Engl J Med 374(13):1296.
79 Muhuri PK, Gfroerer JC, Davies C. 2013, August. Associations of nonmedical pain reliever use and initiation of heroin use in the United States. CBHSQ Data Review. Available at http://archive.samhsa.gov/data/2k13/DataReview/DR006/nonmedical -pain-reliever-use-2013.pdf.
80 Al-Tayyib AA, Koester S, Riggs P. 2017. Prescription opioids prior to injection drug use : Comparisons and public health implications. Addict Behav 65:224-228.

DRAFT/ADVISORY/CONSULTATIVE/DELIBERATIVE/CONFIDENTIAL
81 Compton WM, Jones CM, Baldwin GT. 2016. Relationship between nonmedical prescription -opioid use and heroin use. N Engl J Med 374(2):154-63.
82 Muhuri PK, Gfroerer JC, Davies C. 2013, August. Associations of nonmedical pain reliever use and initiation of heroin use in the United States. CBHSQ Data Review. Available at http://archive.samhsa.gov/data/2k13/DataReview/DR006/nonmedical-pain-reliever-use-2013.pdf
83 Cerdá M, Santaella J, Marshall BD, Kim JH, Martins SS. 2015. Nonmedical prescription opioid use in childhood and early adolescence predicts transitions to heroin use in young adulthood: A national study. J Pediatr 167(3):605-12.
84 https://www.cdc.gov/vitalsigns/heroin/infographic.html#graphic
85 Cicero TJ, Ellis MS, Kasper ZA. 2017. Increased use of heroin as an initiating opioid of abuse. Addict Behav 74:63-66.
86 Cicero TJ, Ellis MS, Kasper ZA. 2017. Psychoactive substance use prior to the development of iatrogenic opioid abuse: A descriptive analysis of treatment-seeking opioid abusers. Addict Behav 65:242-244.
87 Martins SS, Sarvet A, Santaella-Tenorio J, Saha T, Grant BF, Hasin DS. 2017. Changes in lifetime heroin use and heroin use disorder: Prevalence from the 2001-2002 to 2012-2013 National Epidemiologic Survey on Alcohol and Related Conditions. JAMA Psychiatry 74(5):445-455
88 Cicero TJ, Ellis MS, Kasper ZA. Increased use of heroin as an initiating opioid of abuse. Addict Behav. 2017 Nov;74:63-66
89 Hser YI, Evans E, Grella C, Ling W, Anglin D. Long-term course of opioid addiction. Harv Rev Psychiatry. 2015 Mar-Apr;23(2):76-89.
90 Degenhardt L, Bucello C, Mathers B, Briegleb C, Ali H, Hickman M, McLaren J. Mortality among regular or dependent users of heroin and other opioids: a systematic review and meta-analysis of cohort studies. Addiction. 2011 Jan;106(1):32-51.
91 Robins LN, Slobodyan S. Post-Vietnam heroin use and injection by returning US veterans: clues to preventing injection today. Addiction 2003; 98: 1053­60.
92 Robins LN, Davis DH, Goodwin DW. Drug use by U.S. Army enlisted men in Vietnam: a follow-up on their return home. Am J Epidemiol 1974; 99: 235­49.
93 Grella CE, Lovinger K. 30-year trajectories of heroin and other drug use among men and women sampled from methadone treatment in California. Drug Alcohol Depend 2011; 118: 251­8.
94 Hser YI. Predicting long-term stable recovery from heroin addiction: findings from a 33-year follow-up study. J Addict Dis 2007; 26: 51­60.
95 Scherbaum N, Specka M. Factors influencing the course of opiate addiction. Int J Methods Psychiatr Res 2008; 17 suppl 1: S39­44.
96 Hser YI, Evans E, Grella C, Ling W, Anglin D. Long-term course of opioid addiction. Harv Rev Psychiatry. 2015 Mar-Apr;23(2):76-89.
97 Waldorf D. Natural recovery from opiate addiction: some social-psychological processes of untreated recovery. J Drug Issues 1983; 13: 237­80.
98 Hser YI, Evans E, Grella C, Ling W, Anglin D. Long-term course of opioid addiction. Harv Rev Psychiatry. 2015 Mar-Apr;23(2):76-89.
99 Ries R, Krupski A, West II, Maynard C, Bumgardner K, Donovan D, Dunn C, Roy-Byrne P. 2015. Correlates of opioid use in adults with self-reported drug use recruited rrom public safety-neet primary care clinics. J Addict Med 9(5):417-26.
100 McHugh RK, Votaw VR, Bogunovic O, Karakula SL, Griffin ML, Weiss RD. 2017. Anxiety sensitivity and nonmedical benzodiazepine use among adults with opioid use disorder. Addict Behav 65:283-288.
101 Scheidegger C, Zimmerli W. Incidence and spectrum of severe medical complications among hospitalized HIV seronegative and HIV seropositive narcotic drug users. AIDS 1996;10:1407­14.

DRAFT/ADVISORY/CONSULTATIVE/DELIBERATIVE/CONFIDENTIAL
102 Ronan MV, Herzig SJ. Hospitalizations related to opioid abuse/ dependence and associated serious infections increased sharply, 2002­12. Health Aff (Millwood) 2016;35:832­7.
103 Suryaprasad AG, White JZ, Xu F, Eichler BA, Hamilton J, Patel A, Hamdounia SB, Church DR, Barton K, Fisher C, Macomber K, Stanley M, Guilfoyle SM, Sweet K, Liu S, Iqbal K, Tohme R, Sharapov U, Kupronis BA, Ward JW, Holmberg SD. Emerging epidemic of hepatitis C virus infections among young nonurban persons who inject drugs in the United States, 2006-2012. Clin Infect Dis. 2014 Nov 15;59(10):1411-9.
104 Fleischauer AT, Ruhl L, Rhea S, Barnes E. 2017. Hospitalizations for endocarditis and associated health care costs among persons with diagnosed drug dependence - North Carolina, 2010-2015. Morb Mortal Wkly Rep 66(22):569-573.
105 Broz D, Wejnert C, Pham HT, DiNenno E, Heffelfinger JD, Cribbin M, Krishna N, Teshale EH, Paz -Bailey G; National HIV Behavioral Surveillance System Study Group. HIV infection and risk, prevention, and testing behaviors among injecting drug users -- National HIV Behavioral Surveillance System, 20 U.S. cities, 2009.
MMWR Surveill Summ. 2014 Jul 4;63(6):1-51. 106 Bach AG, Jordan B, Wegener NA, Rusner C, Kornhuber M, Abbas J, Surov A. 2012. Heroin spongiform
leukoencephalopathy (HSLE). Clin Neuroradiol 22(4):345-9. 107 Borne J, Riascos R, Cuellar H, Vargas D, Rojas R. 2005. Neuroimaging in drug and substance abuse part II:
opioids and solvents. Top Magn Reson Imaging 16(3):239-45. 108 Fareed A, Kim J, Ketchen B, Kwak WJ, Wang D, Shongo-Hiango H, Drexler K. 2017. Effect of heroin use on
changes of brain functions as measured by functional magnetic resonance imaging, a systematic review. J Addict Dis 36(2):105-116. 109 Lefaucheur R, Lebas A, Gérardin E, Grangeon L, Ozkul-Wermester O, Aubier-Girard C, Martinaud O, Maltête D. 2017. Leucoencephalopathy following abuse of sniffed heroin. J Clin Neurosci 35:70-72. 110 Corr TE, Hollenbeak CS. 2017. The economic burden of neonatal abstinence syndrome in the United States. Addiction 112(9):1590-1599.
111 Corr TE, Hollenbeak CS. The economic burden of neonatal abstinence syndrome in the United States. Addiction. 2017 Sep;112(9):1590-1599.
112 Callaghan T, Crimmins J, Schweitzer RD. Children of substance-using mothers: child health engagement and child protection outcomes. J Paediatr Child Health. 2011;47(4):223­227.
113 Child Welfare Information Gateway. 2016. Parental Drug Use as Child Abuse. U.S. Department of Health an d Human Services, Children's Bureau. Washington, DC. Accessed at https://www.childwelfare.gov/pubPDFs/drugexposed.pdf on October 25, 2017.
114 Solis JM, Shadur JM, Burns AR, Hussong AM. Understanding the diverse needs of children whose parents abuse substances. Curr Drug Abuse Rev. 2012Jun;5(2):135-47.
115 Krueger, AB. 2017. Where Have All The Workers Gone? An Inquiry into the Decline of the U.S. Labor Force Participation Rate. Brookings Papers on Economic Activity. Accessed at https://www.brookings.edu/wpcontent/uploads/2017/09/1_krueger.pdf on October 25, 2017.
116 Curtis S. Florence, Chao Zhou, Feijun Luo, Likang Xu. 2016. The economic burden of prescription opioid overdose, abuse, and dependence in the United States, 2013. Medical Care 54 (10): 901
117 CDC National Center for Health Statistics. 2017. Provisional Counts of Drug Overdose Deaths, as of 8/6/2017. Accessed at https://www.cdc.gov/nchs/data/health_policy/monthly-drug-overdose-death-estimates.pdf on September 5, 2017.
118 Brady JE, Giglio R, Keyes KM, DiMaggio C, Li G. 2017. Risk markers for fatal and non-fatal prescription drug overdose: a meta-analysis. Inj Epidemiol 4(1):24.
119 Brady JE, Giglio R, Keyes KM, DiMaggio C, Li G. 2017. Risk markers for fatal and non-fatal prescription drug overdose: a meta-analysis. Inj Epidemiol 4(1):24.
120 O'Donnell JK, Halpin J, Mattson CL, Goldberger BA, Gladden RM. Deaths Involving Fentanyl, Fentanyl Analogs, and U-47700 -- 10 States, July­December 2016. MMWR Morb Mortal Wkly Rep. ePub: 27 October 2017. DOI: http://dx.doi.org/10.15585/mmwr.mm6643e1

DRAFT/ADVISORY/CONSULTATIVE/DELIBERATIVE/CONFIDENTIAL

121 Data on facilities from the Substance Abuse and Mental Health Services Administration. National Survey of Substance Abuse Treatment Services information on the Behavioral Health Treatment Services Locator, available at https://findtreatment.samhsa.gov/. Extracted by ONDCP on February 10, 2016; county levels of urbanization are from the National Center for Health Statistics classification.

122 Data on physicians from the Drug Enforcement Administration, unpublished data provided to ONDCP as of February 16, 2016; county levels of urbanization are from the National Center for Health Statistics classification.

123 Pullen E and Oser C. 2014. Barriers to Substance Abuse Treatment in Rural and Urban Communities: Counselor Perspectives. Substance Use and Misuse 49:891-901.

124 Cummings JR, Wen H, Ko M, and Druss BG. 2014. Race/Ethnicity and Geographic Access to Medicaid Substance Use Disorder Treatment Facilities in the United States. JAMA Psychiatry 71(2):190-196.

125 Washington State Institute for Public Policy (May 2017). Benefit-cost technical documentation. Olympia, WA. http://www.wsipp.wa.gov/TechnicalDocumentation/WsippBenefitCostTechnicalDocumentation.pdf

126 Ryan SM, Jorm AF, Lubman DI. 2010. Parenting factors associated with reduced adolescent alcohol use: a systematic review of longitudinal studies. Aust N Z J Psychiatry 44:774­783.

127 an der Vorst H, Engels RC, Meeus W, Dekovic M. 2006. The impact of alcohol-specific rules, parental norms
about early drinking and parental alcohol use on adolescents' drinking behavior. J Child Psychol Psychiatry;47:1299­1306.

128 National Survey of American Attitudes on Substance Abuse XVI: Teens and Parents; National Center on Addiction and Substance Abuse at Columbia University; August 2011.

129 PATS, 2011.

130Substance Abuse and Mental Health Services Administration. 2017. Results from the 2016 National Survey on

Drug Use and Health: Detailed Tables.

Table 6.53B. Retrieved from

https://www.samhsa.gov/data/sites/default/files/NSDUH-DetTabs-2016/NSDUH-DetTabs-2016.pdf, accessed on

October 26, 2017.

131 Substance Abuse and Mental Health Services Administration. 2017. Results from the 2016 National Survey on Drug Use and Health: Detailed Tables. Table 3.29B. Retrieved from https://www.samhsa.gov/data/sites/default/files/NSDUH-DetTabs-2016/NSDUH-DetTabs-2016.pdf, accessed on October 26, 2017.

132 Substance Abuse and Mental Health Services Administration. 2017. Results from the 2016 National Survey on

Drug Use and Health: Detailed Tables.

Table 3.29B. Retrieved from

https://www.samhsa.gov/data/sites/default/files/NSDUH-DetTabs-2016/NSDUH-DetTabs-2016.pdf, accessed on

October 26, 2017.

133 Smit E, Verdurmen J, Monshouwer K, Smit F. 2008. Family interventions and their effect on adolescent alcohol use in general populations; a meta-analysis of randomized controlled trials. Drug Alcohol Depend 97:195­206.

134 Mednick SC, Christakis NA, Fowler JH. The spread of sleep loss influences drug use in adolescent social networks. PLoS One. 2010 Mar 19;5(3):e9775.

135 NIDA (2016). Principles of Substance Abuse Prevention for Early Childhood. Retrieved from https://www.drugabuse.gov/publications/principles-substance-abuse-prevention-early-childhood on 2017, September 6.

136 Bradshaw, C. P., Zmuda, J. H., Kellam, S. G., & Ialongo, N. S. 2009. Longitudinal impact of two universal
preventive interventions in first grade on educational outcomes in high school. Journal of Educational Psychology 101(4), 926-937.

137 Hawkins, J. D., Catalano, R. F., Kosterman, R., Abbott, R., & Hill, K. G. 1999. Preventing Adolescent Health Risk Behaviors by Strengthening Protection During Childhood. Archives of Pediatrics & Adolescent Medicine 153(3).

138 Hawkins, D. 1967. On Understanding the Understanding of Children. Archives of Pediatrics & Adolescent Medicine, 114(5), 513.

DRAFT/ADVISORY/CONSULTATIVE/DELIBERATIVE/CONFIDENTIAL
139 Hawkins, J. D., Arthur, M. W., & Catalano, R. F. 1995. Preventing substance abuse. Crime and Justice: A Review of Research, 19, 343-428.
140 Spoth, R., Randall, G. K., & Shin, C. 2008. School Psychology Quarterly, 23(1), 70-89 141 Kuklinski, Margaret R., et al. 2012. "Cost-benefit analysis of Communities That Care outcomes at eighth grade."
Prevention Science 13.2: 150-161. 142 Lockman, J. E., & Wells, K. C. 2002. Contextual social­cognitive mediators and child outcome: A test of the
theoretical model in the Coping Power program. Development and Psycho.pathology, 14(04), 945-967.
143 Catalano, R. F., Haggerty, K. P., Fleming, C. B., & Skinner, M. L. (2007). Focus on Families. Therapist's Guide to Evidence-Based Relapse Prevention, 237-257.
144 NIDA. 2016. Principles of Substance Abuse Prevention for Early Childhood. Retrieved from https://www.drugabuse.gov/publications/principles-substance-abuse-prevention-early-childhood on 2017, September 6.
145 HHS. 2017. Facing Addiction in America. U. S. Surgeon General's Report on Alcohol, Drugs, and Health. Retrieved from https://addiction.surgeongeneral.gov/.
146 HHS. 2017. Facing Addiction in America. U. S. Surgeon General's Report on Alcohol, Drugs, and Health. Retrieved from https://addiction.surgeongeneral.gov/.
147 Madras BK. 2010, Feb. Office of National Drug Control Policy: a scientist in drug policy in Washington, DC. Ann N Y Acad Sci. 1187:370-402.
148 Knight JR, Harris SK, Sherritt L, Van Hook S, Lawrence N, Brooks T, Carey P, Kossack R, Kulig J. 2007, Nov. Prevalence of positive substance abuse screen results among adolescent primary care patients. Arch Pediatr Adolesc Med. 161(11):1035-41.
149 Ramos MM, Sebastian RA, Murphy M, Oreskovich K, Condon TP. 2017, Apr-Jun. Adolescent substance use: Assessing the knowledge, attitudes, and practices of a school-based health center workforce. Subst Abus. 38(2):230-236.
150 Harris BR, Shaw BA, Sherman BR, Lawson HA. 2016. Screening, brief intervention, and referral to treatment for adolescents: Attitudes, perceptions, and practice of New York school-based health center providers. Subst Abus. 37(1):161-7.
151 Mitchell AM, Fioravanti M, Kane I, Puskar K, Hagle H, Boucek L. 2015, Jun. A call for universal alcohol, drug screening. Am J Nurs. 115(6):11.
152 Farrelly, MC, Niederdeppe, J, & Yarsevich, J. (2003). Youth tobacco prevention mass media campaigns: Past, present, and future directions, BMJ: TC, Accessed at: http://tobaccocontrol.bmj.com/content/12/suppl_1/i35.
153 Gibson, LA, Parvanta, SA, Jeong, M, & Hornik RC. (2014). Evaluation of a mass media campaign promoting using help to quit smoking, American Journal of Preventive Medicine, 4(5): 487-495.
154 Das, JK, et al. (2016). Interventions for adolescent substance abuse: An overview of systematic reviews, Journal of Adolescent Health, 59: s61-75.
155 Scheier LM and Grenard JL (2010). Influence of a nationwide social marketing campaign on adolescent drug use, Journal of Health Communication, 12(3) 240-271.
156 Orwin, R. Cadell, D, Chu, A, Kalton, G, Maklan, D, Morin, C, Piesse, A, Sridharan, S, Steele, D, Taylor, K, & Tracy, E. (2006). Evaluation of the National Youth Anti-Drug Media Campaign: 2004 Report of Findings, National Institutes of Health, National Institute on Drug Abuse; Bethesda, MD. Accessed at: https://archives.drugabuse.gov/initiatives/westat/NSPY2004Report/Vol1/Report.pdf
157 Allara, E. et al. (2015). Are mass-media campaigns effecting in preventing drug use? A Cochrane systematic review and meta-analysis, British Medical Journal Open, 5:e007449.doi:10.1136/bmjopen-2014-007449.
158 Stephenson, MT. (2009). Sensation seeking as a moderator of the processing of anti-heroin PSA's, Journal of Communication Studies, 53(4): 358-380.
159 Palmgreen, P., Donohew, L, Lorch, EP, Hoyle, RH, & Stephenson, MT, (2001). Television campaigns and adolescent marijuana use: Tests of sensation seeking targeting, American Journal of Public Health, 91, 292-296.

DRAFT/ADVISORY/CONSULTATIVE/DELIBERATIVE/CONFIDENTIAL
160 Farrelly MC, Duke JC, Nonnemaker J, et al. Association Between The Real Cost Media Campaign and Smoking Initiation Among Youths -- United States, 2014­2016. MMWR Morb Mortal Wkly Rep 2017;66:47­50. DOI: http://dx.doi.org/10.15585/mmwr.mm6602a2
161 Neil Seeman, personal communication 162 Newton NC, Champion KE, Slade T, Chapman C, Stapinski L, Koning, Tonks Z, Teesson M. 2017, May. A
systematic review of combined student- and parent-based programs to prevent alcohol and other drug use among adolescents. Drug Alcohol Rev. 36(3):337-351. 163 Centers For Disease Control And Prevention Public Health Service U S Department Of Health And Human Services. Guideline for Prescribing Opioids for Chronic Pain. J Pain Palliat Care Pharmacother. 2016, Jun;30(2):138-40. 164 National Academies of Sciences, Engineering, and Medicine. 2017. Pain Management and the Opioid Epidemic: Balancing Societal and Individual Benefits and Risks of Prescription Opioid Use. Washington, DC: The National Academies Press. Page 70. doi: https://doi.org/10.17226/24781. 165 Guy,GP, Zhang, K, Bohm, MK, Losby, J, Lewis, B, Young, R, Murphy, LB, & Dowell, D. (2017). Vital signs: Changes in opioid prescribing in the United States, 2006-2015. Morbidity and Mortality Weekly (MMWR). 66(26); 697-704. 166 VA and DoD. (2017). VA/DoD Clinical Practice Guideline for Opioid Therapy for Chronic Pain. Version 3.0. Retrieved at https://www.healthquality.va.gov/guidelines/pain/cot/. 167 https://www.ama-assn.org/delivering-care/reversing-opioid-epidemic 168 https://www.asam.org/education/resources/Opioid-Prescribing 169 http://www.aafp.org/patient-care/clinical-recommendations/all/opioid-prescribing.html 170 https://pcss-o.org/ 171 https://www.samhsa.gov/medication-assisted-treatment/training-resources/opioid-courses 172https://www.drugabuse.gov/nidamed-medical-health-professionals/tool-resources-your-practice/other-opioidprescribing-resources 173 National Governor's Association. 2016, July. A Compact to Fight Opioid Addiction. Retrieved at https://www.nga.org/cms/news/2016/opioid-compact. 174 Marcus, P.A., Thomas, A.L. (2017). Prudent Prescribing: An Overview of Recent Federal and State Guidelines for Opioid Prescriptions. American Bar Association Health eSource. Opioid Epidemic Special Edition. 13(12). Retrieved at https://www.americanbar.org/publications/aba_health_esource/20162017/opioids/prescriptions.html. 175 An Act Relative to Substance Use, Treatment, Education and Prevention. Chapter 52. Massachusetts Session Law. 2016. Retrieved at https://malegislature.gov/Laws/SessionLaws/Acts/2016/Chapter52. 176 State of Washington Department of Health. WSR-11-12-025. Permanent Rules. Medical Quality Assurance Commission. Retrieved at http://apps.leg.wa.gov/documents/laws/wsr/2011/12/11-12-025.htm. 177 Boston Globe and Harvard T.H. Chan School of Public Health. Prescription painkiller abuse: Att itudes among adults in Massachusetts and the United States. May 2015. https://cdn1.sph.harvard.edu/wp content/uploads/sites/21/2015/05/Prescription-Painkiller-Poll-Report.pdf. 178 Commonwealth of Massachusetts Department of Public Health. Stop addiction in its tracks: Current statistics. 2016. http://www.mass.gov/eohhs/gov/departments/dph/stop-addiction/current-statistics.html. 179 Avorn J, Chen M, Hartley R. 1982, Jul. Scientific versus commercial sources of influence on the prescribing behavior of physicians. Am J Med. 73(1):4-8. 180 Baker JA, Avorn J, Levin R, Bateman BT. 2016, Apr 19. Opioid Prescribing After Surgical Extraction of Teeth in Medicaid Patients, 2000-2010. JAMA. 315(15):1653-4. 181 Bateman BT, Franklin JM, Bykov K, Avorn J, Shrank WH, Brennan TA, Landon JE, Rathmell JP, Huybrechts KF, Fischer MA, Choudhry NK. Persistent opioid use following cesarean delivery: patterns and predictors among opioid-naïve women. Am J Obstet Gynecol. 2016 Sep;215(3):353.e1-353.e18.

DRAFT/ADVISORY/CONSULTATIVE/DELIBERATIVE/CONFIDENTIAL

182 www.DrugEpi.org
183 Gilson, AM. (2009). Pharmacists and controlled substances prescriptions, Medscape, Accessed at: http://www.medscape.com/viewarticle/701794
184 Nam YH, Shea DG, Shi Y, Moran JR. 2017, May. State prescription drug monitoring programs and fatal drug overdoses. Am J Manag Care. 23(5):297-303.
185 Christina Cook, Lekan Wang, Alex Boras (Palantir) personal communication, June 2017.
186 IMS Health, National Prescription Audit (NPATM). Cited in internal document: Preliminary Update on Opioid Pain Reliever (OPR) Prescription Rates Nationally and by State: 2010-2013.
187 Lipari, R.N. and Hughes, A. How people obtain the prescription pain relievers they misuse. The CBHSQ Report: January 12, 2017. Center for Behavioral Health Statistics and Quality, Substance Abuse and Mental Health Services Administration, Rockville, MD.
188 http://www.hcahpsonline.org/home.aspx
189 https://www.medicare.gov/hospitalcompare/about/what-is-HOS.html
190

191 Jena AB1, Goldman D2, Karaca-Mandic P3. 2016, Jul 1. Hospital Prescribing of Opioids to Medicare Beneficiaries JAMA Intern Med. 176(7):990-7. doi: 10.1001/jamainternmed.2016.2737.

192 Jena AB1, Goldman D2, Karaca-Mandic P3. 2016, Jul 1. Hospital Prescribing of Opioids to Medicare Beneficiaries JAMA Intern Med. 176(7):990-7. doi: 10.1001/jamainternmed.2016.2737.

193 Chughtai M1, Jauregui JJ1, Mistry JB1, Elmallah RK1, Diedrich AM1, Bonutti PM2, Delanois R1, Mont MA1.
2016, Apr. What Influences How Patients Rate Their Hospital After Total Knee Arthroplasty? Surg Technol Int. 28:261-5.

194 Mistry JB, Chughtai M, Elmallah RK, Le S, Bonutti PM, Delanois RE, Mont MA. 2016, Nov. What Influences How Patients Rate Their Hospital After Total Hip Arthroplasty? J Arthroplasty. 31(11):2422-2425. doi: 10.1016/j.arth.2016.03.060. Epub 2016 Apr 13. PMID: 27155998.

195 Substance Abuse and Mental Health Services Administration. 2017. Results from the 2016 National Survey on

Drug Use and Health: Detailed Tables.

Table 7.2A. Retrieved from

https://www.samhsa.gov/data/sites/default/files/NSDUH-DetTabs-2016/NSDUH-DetTabs-2016.pdf, accessed on

October 26, 2017.

196 What America's Users Spend on Illegal Drugs: 2000-2010, RAND for ONDCP, Fen 2014

197 Sullum, J., How Many Daily Heroin Users Are There In The U.S.? Somewhere Between 60,000 And 1 Milli on. Maybe., Forbes, March 10, 2014

198 U.S. Department of Justice, Drug Enforcement Administration. STARLiMS forensic drug chemistry database. Analysis by ONDCP on export through May 15, 2017. These counts are not representative off all seized fentanyl tablets and capsules in the United States (or specific geographic regions), but are representative of all evidence submitted and analyzed by DEA laboratories from domestic sources.

199 Kyle Soska and Nicolas Christin, Measuring the Longitudinal Evolution of t he Online Anonymous Marketplace Ecosystem, Carnegie Mellon University, August 13, 2015, Accessed on September 19, 2016, http://www.usinex.org/conference/usinexsecurity15/technical-sessions/presentation/soska.

200 Madras BK. The Surge of Opioid Use, Addiction, and Overdoses: Responsibility and Response of the US Health Care System. JAMA Psychiatry. 2017 May1;74(5):441-442.

201 Madras BK, Compton WM, Avula D, Stegbauer T, Stein JB, Clark HW. Screening, brief interventions, referral to treatment (SBIRT) for illicit drug and alcohol use at multiple healthcare sites: comparison at intake and 6 months later. Drug Alcohol Depend. 2009 Jan 1;99(1-3):280-95.

202 NIDA. 2012, December 1. Principles of Drug Addiction Treatment: A Research-Based Guide (Third Edition). Retrieved from https://www.drugabuse.gov/publications/principles-drug-addiction-treatment-research-basedguide-third-edition on 2017, September 6

DRAFT/ADVISORY/CONSULTATIVE/DELIBERATIVE/CONFIDENTIAL
203 Glasner-Edwards, S., Rawson, R. 2010. Evidence-based practices in addiction treatment: Review and recommendations for public policy. Health Policy. 97. 93-104
204 Miller, S. M., Moulton, S. 2014. Publicness in Policy Environments: A Multilevel Analysis of Substance Abuse Treatment Services, Journal of Public Administration Research and Theory, 2014, 24, 3, 553
205 Summary of treatment requirements provided by Dr, Shelly Greenfield, McLean Hospital.
206 Lagisetty P, Klasa K, Bush C, Heisler M, Chopra V, Bohnert A. Primary care models for treating opioid use disorders: What actually works? A systematic review. PLoS One. 2017 Oct 17;12(10):e0186315.
207 Lorman, W.J. 2013. Maintaining Sobriety and Recovery, Nursing Clinics of North America, 2013, 48, 3, 437 208 Duffy, P., Baldwin, H. 2013. Recovery post treatment: plans, barriers and motivators, Substance Abuse
Treatment, Prevention, and Policy, 2013, 8, 1, 6 209National Quality Forum. 2017. Behavioral Health 2016-2017: final Technical Report.
https://www.qualityforum.org/Publications/2017/08/Behavioral_Health_2016-2017_Final_Report.aspx
210 Garnick, D., Horgan, C., & Chalk, M. 2006. Performance measures for alcohol and other drug services. Alcohol Research & Health, 29(1), 19-26Retrieved from https://pubs.niaaa.nih.gov/publications/arh291/19-26.htm
211 ASAM. 2005.Principles for Outcome Evaluation in the Treatment of Substance-Related Disorders: a Joint AMBHA-ASAM Statement. Retrieved from https://www.asam.org/docs/default-source/public-policystatements/1outcome-evaluation-1-012.pdf?sfvrsn=0
212 Mattick, R.P., et al. 2014. Buprenorphine maintenance versus placebo or methadone maintenance for opioid dependence. Cochrane Database Syst Rev (2): p. Cd002207.
213 Rosenblum, A., et al., Distance traveled and cross-state commuting to opioid treatment programs in the United States. J Environ Public Health, 2011. 2011: p. 948789.
214 Gibson, A., et al. 2008. Exposure to opioid maintenance treatment reduces long-term mortality. Addiction 103(3): p. 462-8.
215 Kermack, A., et al. 2017. Buprenorphine prescribing practice trends and attitudes among New York providers. J Subst Abuse Treat 74: p. 1-6.
216 Mark, T.L., et al., Medicaid coverage of medications to treat alcohol and opioid dependence. J Subst Abuse Treat, 2015. 55: p. 1-5.
217 Mardsen, J. et al. 2017. Does exposure to opioid substitution treatment in prison reduce the risk of death after release? A national prospective observational study in England. Addiction. 112(8):1408-1418.
218 Bart, G. 2012. Maintenance medication for opiate addiction: The foundation of recovery. Journal of Addictive Diseases, 31(3), 207­225.
219 Fullerton, C. A., Kim, M., Thomas, C. P., Lyman, D. R., Montejano, L. B., Dougherty, R. H., ... Delphin -Rittmon, M. E. 2014. Medication-assisted treatment with methadone: Assessing the evidence. Psychiatric Services, 65(2), 146­157.
220 MacArthur, G. J., Minozzi, S., Martin, N., Vickerman, P., Deren, S., Bruneau, J., ... Hickman, M. 2012. Opiate substitution treatment and HIV transmission in people who inject drugs: Systematic review and meta-analysis. BMJ, 345, e5945.
221 Woody, G. E., Bruce, D., Korthuis, P. T., Chhatre, S., Poole, S., Hillhouse, M., ... Ling, W. 2014. HIV risk reduction with buprenorphine-naloxone or methadone: Findings from a randomized trial. Journal of Acquired Immune Deficiency Syndromes, 66(3), 288­293.
222 World Health Organization. 2009. Guidelines for the psychosocially assisted pharmacological treatment of opioid dependence. Geneva, Switzerland: WHO Press.
223 Schwartz, R. P., Jaffe, J. H., O'Grady, K. E., Kinlock, T. W., Gordon, M. S., Kelly, S. M., Ahmed, A. 2009. Interim methadone treatment: Impact on arrests. Drug and Alcohol Dependence, 103(3), 148­154.
224 Soyka, M., Träder, A., Klotsche, J., Haberthür, A., Bühringer, G., Rehm, J., & Wittchen, H. U. (2012). Criminal behavior in opioid-dependent patients before and during maintenance therapy: 6-year follow-up of a nationally representative cohort sample. Journal of Forensic Sciences, 57(6), 1524­1530.

DRAFT/ADVISORY/CONSULTATIVE/DELIBERATIVE/CONFIDENTIAL

225 Friedmann PD, Hoskinson R, Jr, Gordon M, Schwartz R, et al. (2012). Medication-Assisted Treatment in criminal justice agencies affiliated with the Criminal Justice-drug Abuse Treatment Studies (CJ-DATS): Availability, barriers and intentions. Subst Abuse. 33:9­18.

226 Belenko, S. et al. (2013). Treating Substance Use Disorders in the Criminal Justice System. Curr Psychiatry Rep. 15(11).

227 McMillan G.P., Lapham S.C. (2005). Staff perspectives on methadone maintenance therapy (MMT) in a large southwestern jail. Addict Res Theory. 13:53­63.

228 Center for Behavioral Health Statistics and Quality. 2017. Key substance use and mental health indicators in the

United States: Results from the 2016 National Survey on Drug Use and Health (HHS P ublication No. SMA 16-

4984, NSDUH

Series

H-51).

Retrieved

from

http://www.samhsa.gov/data/(https://www.samhsa.gov/data/sites/default/files/NSDUH-FFR1-2016/NSDUH-

FFR1-2016.htm#tx1)

229 Marlowe D, Hardin C, Fox C. 2016. Painting the Current Picture: A National Report on Drug Courts and Other Problem-Solving Courts in the United States, National Drug Court Institute. Alexandria, VA. Retrieved from https://www.ndci.org/wp-content/uploads/2016/05/Painting-the-Current-Picture-2016.pdf

230 Weiss AJ, Elixhauser A, Barrett ML, Steiner CA, Bailey MK, O'Malley L. Opioid Related Inpatient Stays and Emergency Department Visits by State, 20019-2014, HCUP Statistical Brief #219. December 2016. Agency for Healthcare Research and Quality. Rockville, MD.

231 Ali, M. M., Mutter, R. (2016). The CBHSQ Report: Patients Who Are Privately Insured Receive Limited Followup Services After Opioid-Related Hospitalizations. Rockville, MD: Substance Abuse and Mental Health Services Administration, Center for Behavioral Health Statistics and Quality.

232 Substance Abuse and Mental Health Services Administration. 2017. Results from the 2016 National Survey on Drug Use and Health: Detailed Tables. Retrieved from https://www.samhsa.gov/data/sites/default/files/NSDUHDetTabs-2016/NSDUH-DetTabs-2016.pdf, accessed on October 26, 2017

233https://www.whitehouse.gov/the-press-office/2017/06/15/presidential-executive-order-expanding-apprenticeshipsamerica

234 Walsh SL, Nuzzo PA, Babalonis S, Casselton V, Lofwall MR. 2016, May 1. Intranasal buprenorphine alone and in combination with naloxone: Abuse liability and reinforcing efficacy in physically dependent opi oid abusers. Drug Alcohol Depend. 162:190-8.

235 Degenhardt L, Larance B, Peacock A, Farrell M. 2015, Nov 2. Reducing extramedical use and harms of pharmaceutical opioids: the potential role of abuse-deterrent formulations. Lancet Psychiatry. (11):957-9.

236https://static1.squarespace.com/static/57b13af320099e871dd94dc8/t/57c31e2fe4fcb561cb850b86/1472405052315 /2016+naloxone+coprescription.pdf

237 Kortenkamp, K., and Ehrle, J. 2002. The well-being of children Involved with the child welfare system: A national overview, New Federalism, Series B, No. B-43. Washington, D.C.: The Urban Institute. ttp://www.urban.org/UploadedPDF/310413_anf_b43.pdf

238 CDC. 2016 Morbidity and Mortality Weekly Report(MMWR) Incidence of Neonatal Abstinence Syndrome. Retrieved from https://www.cdc.gov/mmwr/volumes/65/wr/mm6531a2.htm

239 Castedo, S. Holleran Steiker, L. (in press). Collegiate Recovery Programs. In Smith, D.C., (Ed.), Emerging Adults in Substance Use Disorder Treatment. New York: Oxford University Press.

240 Forrest, C.E. (2016). Collateral Consequences of a Criminal Conviction: Impact on Corrections and Reentry. NIJ Update. Corrections Today. American Correctional Association

241 The National Council of State Governments Justice Center. National Inventory of Collateral Consequences of Conviction. Website. https://niccc.csgjusticecenter.org/map/

242 Policin, D.L. et al. (2010). Sober Living Houses for Alcohol and Drug Dependence: 18 - Month Outcomes. Journal of Substance Abuse Treatment. 38(4): 356­365.

243 Volkow ND, Collins FS. 2017, Jul 27. The Role of Science in Addressing the Opioid Crisis. N Engl J Med. 377(4):391-394.

DRAFT/ADVISORY/CONSULTATIVE/DELIBERATIVE/CONFIDENTIAL
244 Volkow ND, Collins FS. The Role of Science in Addressing the Opioid Crisis. N Engl J Med. 2017 Jul 27;377(4):391-394.
245 Skolnick P. The Opioid Epidemic: Crisis and Solutions. Annu Rev Pharmacol Toxicol. 2017 Oct 2. [Epub ahead of print]
246 Massey J, Kilkenny M, Batdorf S, Sanders SK, Ellison D, Halpin J, Gladden RM, Bixler D, Haddy L, Gupta R. 2017, Sep 22. Opioid Overdose Outbreak - West Virginia, August 2016. MMWR Morb Mortal Wkly Rep. 66(37):975-980
247 Volkow ND, Frieden TR, Hyde PS, Cha SS. 2014. Medication-assisted therapies -- tackling the opioid-overdose epidemic. N Engl J Med 370: 2063-6.
248 Hser YI, Evans E, Huang D, Weiss R, Saxon A, Carroll KM, Woody G, Liu D, Wakim P, Matthews AG, Hatch Maillette M, Jelstrom E, Wiest K, McLaughlin P, Ling W. 2016, Apr. Long-term outcomes after randomization to buprenorphine/naloxone versus methadone in a multi-site trial. Addiction. 111(4):695-705.
249 Weiss RD, Rao V. 2017, Apr 1. The Prescription Opioid Addiction Treatment Study: What have we learned. Drug Alcohol Depend. 173 Suppl 1:S48-S54.
250 Wang J, Fang H, Carreiro S, Wang H, Boyer E. 2017, Jan. A New Mining Method to Detect Real Time Substance Use Events from Wearable Biosensor Data Stream. Int Conf Comput Netw Commun. 2017:465-470.
251 https://www.fda.gov/Drugs/DrugSafety/InformationbyDrugClass/ucm338566.htm 252 Califf RM, Woodcock J, Ostroff S. 2016. A Proactive Response to Prescription Opioid. Abuse N Engl J Med
374:1480-1485 253 Extended-Release and Long-Acting Opioid Analgesics shared system, Risk Evaluation and Mitigation Strategy
(REMS), https://www.fda.gov/downloads/Drugs/DrugSafety/InformationbyDrugClass/UCM348818.pdf 254 Waldhoer M, Bartlett SE, Whistler JL. 2004. Opioid receptors. Annu Rev Biochem 73:953-90. 255 Courtwright, David. 2001. Dark Paradise: A history of Opiate Addiction in America. Harvard University Press. 256 Musto, David F. 1999. The American Disease: Origins of Narcotic Control. Yale University Press. 257 Courtwright DT. 2015, Nov 26. Preventing and Treating Narcotic Addiction--Century of Federal Drug Control. N
Engl J Med. 373(22):2095-7.

